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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
Valdecoxib is an effective treatment option to improve pain in adults with osteoarthritis of the
hip or knee.
STUDY DESIGN: This review consists of three randomized control trials; two were published
in 2002 and the third in 2006.
DATA SOURCES: Sources were studies comparing groups taking Valdecoxib 10mg QD to
placebo, which were found via Pubmed, MEDLINE, Ovid, and Cochrane databases.
OUTCOMES MEASURED: The three articles measured various outcomes: pain improvement,
stiffness, physical improvement, adverse effects, and onset of analgesia during acute pain flare.
Outcomes were measured via the Patient’s Assessment of Arthritis Pain- Visual Analog Scale
(PAAP-VAS), WOMAC osteoarthritis, Patient’s (PaGAA) and Physician’s (PhGAA) Global
Assessment of Arthritis.
RESULTS: Kivitz et al found that Valdecoxib 10mg & 20mg daily doses were similar in
efficacy and both were superior to placebo. Valdecoxib 5mg was not found to be superior to
placebo.5 Makarowski et al also found that Valdecoxib 5mg and 10mg QD were superior to
placebo. They also found that Valdecoxib 10mg QD was superior in efficacy to Valdecoxib 5mg
QD.6 Moskowitz et al found that patients had both a significant improvement in pain at 3 hours
with Valdecoxib as compared to placebo, and a statistically significant increase in percentage of
patients with analgesia after 4hrs compared to placebo.7
CONCLUSION: These three randomized control trials all concluded that Valdecoxib is superior
to placebo in doses of at least 10mg as compared to placebo. Further studies should review safety
of Valdecoxib in a risk/benefit analysis to provide useful conclusions about the continued use of
it for treatment of osteoarthritis.
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INTRODUCTION
Osteoarthritis is a very common condition in the adult and older populations in the US.
Although there are with various forms of treatment focused on symptom improvement, there is
currently no cure for OA.1 Also known as degenerative joint disease, OA is the most common
form of arthritis, classified as Idiopathic or Secondary. Osteoarthritis is usually diagnosed by
symptomatology and radiographic findings, most commonly affecting the hips, knees, hands, and
feet.
In the United States, osteoarthritis affects 13.9% of adults 25 years and older and 33.6%
of those over 65 years.1 In 2005 it was estimated that 26.9 million US adults were affected by
OA. Additionally, in 1997 it was estimated that approximately 409,000 hospitalizations occur
annually with osteoarthritis as the principal diagnosis. Osteoarthritis is the most common cause
of disability in elderly patients in the developed world.2 OA is not only affecting thousands of
patients annually, it is also very costly. Job-related osteoarthritis costs approximately $3.4-13.2
billion per year, and it was estimated that $7.9 billion was spent on hip and knee replacements in
1997.1
Specific causes of OA are unknown, but it is believed to be a result of both mechanical
and molecular events in the affected joint.1 OA is characterized by focal and progressive loss of
hyaline cartilage as well as bony changes like osteophytes, bony sclerosis and joint space
narrowing.1 Patients often experience joint pain, stiffness, and loss of ADLs due to
osteoarthritis.
Initial treatment regimens include moderate physical activity, weight loss, and use of
assistive devices.3 Pharmacologic treatments typically start with oral acetaminophen for mild
disease, and then progress to oral NSAIDs of various strengths including selective COX-2
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inhibitors.3 Diclofenac—a topical NSAID—has also shown some efficacy in knee and hand
OA.3 Other treatment options include intra-articular injections of corticosteroids or sodium
hyaluronate.3 The only curative option for hip and knee arthritis at this point is surgical
replacement of the joint, which has many limitations including cost, lifespan of the replacement
joint, and patient’s ability to undergo major surgery.3
Chronic NSAID use has various side effects including GI upset and ulceration, so it has
been proposed that COX-2 specific inhibitors such as Valdecoxib may be equally as effective
without the adverse affects of non-selective NSAIDs.4 Various studies are looking at the safety
and efficacy of COX-2 specific inhibitors for osteoarthritis patients since their introduction.4
Although Valdecoxib has recently been pulled off the market, it is important still to look at the
effects of all different COX-2 inhibitors to make improvements for the future.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not
Valdecoxib is an effective treatment option to improve pain in adults with osteoarthritis of
the hip or knee.
METHODS
The three articles used in this selective EBM review were found via Ovid, Medline,
Pubmed, and Cochrane databases. All articles selected were published in English in peerreviewed journals between 2002 and 2006, using the keywords “Valdecoxib” and
“osteoarthritis” to search the above mentioned databases. Inclusion criteria for the studies
selected require the use of patient oriented outcomes (POEMs), RCT’s, studies published
after 1996, and those evaluating efficacy of Valdecoxib. Exclusion criteria involved the use
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of DOE outcome measures, studies that looked at pediatric populations, and those that only
looked at safety profiles of Valdecoxib.
All three studies were double blinded, randomized controlled trials looking at adult
populations over the age of 18 with diagnosed osteoarthritis of the hip or knee. The outcomes
measured in these studies were efficacy of Valdecoxib for the treatment of osteoarthritis of
the hip or knee. Each study utilized an intervention of Valdecoxib po daily, although other
interventional drugs were used in comparison as well. The comparison group in every study
reviewed was one that received placebo. Two of the studies evaluated alleviation of pain with
consistent daily use of Valdecoxib, and the third study evaluated onset of analgesia during
acute pain flare with the addition of Valdecoxib. A summary of statistics includes numbers
needed to treat (NNT), mean change from baseline, confidence interval (CI), and p-values.
The demographics of included studies can be found in Table 1.
Table 1: Demographics & Characteristics of included studies
Study

Type

#
pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

Kivitz5

RCT

1,
016

59.8
±
10.9
years

Ambulatory
adults with modsevere OA of the
knee
Pts with baseline
scores >40mm on
PAAP-VAS &
“poor” or “very
poor” on PaGAA
and PhGAA

Pts with inflammatory arthritis,
gout, pseudogout, paget’s, or any
other chronic pain syndrome;
Pts with OA of hip ipsilateral to
Index Knee (IK), severe anserine
bursitis, acute joint trauma,
complete loss of articular cartilage
on IK

Makarowski6

RCT

467

62.4
±
11.8
years

Pts with
symptomatic OA
of the hip: pain +
2 of the
following:
ESR<20mm/ hr,
radiographic
osteophytes, joint
space narrowing;
Baseline PAASVAS ≥ 40
PaGAA or

Pts with inflammatory arthritis,
gout, pseudogout, paget’s, or any
chronic pain syndrome;
Pts with OA of the knee ipsilateral
to the Index Hip (IH), symptomatic
trochanteric bursitis, or acute joint
trauma of IH;
Pts with complete loss of articular
cartilage on WT-bearing xray of IH
Pts with active GI disease, GI tract
ulceration within 30 days of study
medication, or significant bleeding

W
/
D
2
6
9

2
0
9

Intervention

Randomized to
control
(placebo) or
experimental
groups
receiving
Valdecoxib
5mg, 10mg,
20mg QD, or
Naproxen
500mg BID
Randomized
to control
group
(placebo) or
experimental
groups
receiving
Valdecoxib
5mg or 10mg
QD, or
Naproxen
500mg BID
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Mosko
-witz7

RCT

530

63.9
± 9.2
years

PhGAA “poor” or
“very poor”
≥45 years old with
knee OA;
Functional
capacity
classification I or
II; OA in flare
state at baseline
assessment:
defined as ≥3 of
the following:
PAAP-VAS
≥40mm, Lequesne
OA severity index
≥7, PaGAA or
PhGAA of “poor”
or “very poor”

disorder
Inflammatory arthritis or acute joint
trauma of Index Joint (IJ); Hx of
malignancy, active GI disease,
chronic or acute renal/hepatic/
coagulation disorder; Abnl
screening lab values >1.5x the
upper limit for AST or ALT, serum
creatinine ≥2.0, or other lab
abnormality within 14 days of
baseline assessment; Pts who
received oral, IM, or intra-articular
corticosteroids within 8 weeks, or
intra-articular hyaluronic acid in IJ
with in 6 months of study drug
admin; Pts who have taken
anticoagulants, NSAIDs, COX-2
specific inhibitors or analgesic
agents

9
5

Randomized
to control
group
(placebo) or
experimental
groups
receiving
Valdecoxib
10mg QD or
Rofecoxib
25mg QD

OUTCOMES MEASURED
The outcomes measured in the reviewed studies are all Patient Oriented Evidence that
Matters (POEMs); in this case pain improvement and onset of analgesia. Kivitz et al5
measured pain improvement using the Patient’s (PaGAA) and Physician’s (PhGAA) Global
Assessment of Arthritis, Patient’s Assessment of Arthritis Pain- Visual Analog Scale (PAAPVAS), and Western Ontario & McMaster Universities (WOMAC) OA indexes reported by
patients and physicians. In this study, baseline measurements were made for comparison and
then subsequent assessments were done with each tool at 2, 6, and 12 weeks. Analysis was
done by least square mean (LSM) change from baseline and reported as statistically
significant based on p-values and confidence intervals. Makarowski et al6 had a similar
study design for reporting efficacy; they measured mean changes from baseline using
PaGAA, PhGAA, PAAP-VAS and WOMAC scales to report pain improvement. Again,
LSM changes from baseline were reported at 2, 6, and 12 weeks and analyzed via p-values
and confidence intervals compared to placebo. Moskowitz et al7 measured onset of analgesia
during an acute pain flare, defined as ≥3 of the following: PAAP-VAS ≥40mm, Lequesne
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OA severity index ≥7, PaGAA or PhGAA of “poor” or “very poor.” Patients who met
criteria for the study were asked to walk for 10 minutes prior to baseline measurements using
the WOMAC scale. Pain intensity (PI) on a visual analog scale (VAS) was then measured at
0.5, 1.0, 1.5, 2, 3, 4, 5, and 6 hours after administration of study medication, each following a
10-minute walk. Statistical analysis of the data was based on percentage of patients with
“analgesia” at each time interval, defining onset of analgesia as a 25% reduction in PI from
baseline.
RESULTS
In the study done by Kivitz et al,5 1019 patients were recruited from 85 different
primary care and rheumatology specialty settings across the United States and Canada.
Patients were randomized into treatment groups and self-administered oral medications.5
Patients and researchers were blinded during this process.5 For all three studies, statistical
analysis was done on the intent to treat (ITT) population, which included those who
randomized and had taken at least one dose of study medication. This particular study only
included continuous data that could not be converted into dichotomous data.
Three patients did not take any study medication and therefore were not included in
efficacy analysis. Of the 1016 remaining patients, 269 withdrew before the end of the study.
Using the Fisher exact test, it was calculated that 20% of the withdrawals were due to
treatment failure.5 It is noted that patients in the placebo group withdrew at a significantly
faster rate than those in active treatment groups. There were no significant differences in
withdrawal rates across the four active treatment groups.5
The PaGAA and PhGAA assessments are measured on a 5 point categorical scale
where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor. PAAP-VAS is a patient
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questionnaire measured on a scale of 1-100mm where 0=no pain and 100=most severe pain.
The WOMAC indices include pain, stiffness, physical function, and composite; data was
reported for stiffness (scale 0-8) and composite (scale 0-96). In order to establish statistical
significance, the Hochberg procedure was used for Valdecoxib 10mg and 20mg to calculate
p-values. A p-value of 0.05 was used for Valdecoxib 5mg and placebo.5
The LSM change for PaGAA was significantly improved at most assessments for
10mg and 20mg of Valdecoxib QD compared to placebo.5 Valdecoxib 5mg QD did not
reach statistical significance.5 Using the PhGAA, significant improvements were observed at
all doses and assessments. The PAAP-VAS displayed a significant improvement in pain for
Valdecoxib 20mg QD, while 10mg and 5mg daily doses were significantly better than
placebo at all assessments except for week 12.5 The experimental study treatments improved
WOMAC indices compared to placebo at 2, 6, and 12 weeks. Valdecoxib 20mg produce a
statistically significant change in all WOMAC scores compared to placebo. Valdecoxib
10mg daily only showed a statistically significant improvement in indices at week 2.5 Data is
shown in Table 2.
Table 2: Kivitz et al5 least square mean changes from baseline in PaGAA, PhGAA,
PAAP-VAS, and WOMAC indices.

PhGAA§
Baseline Mean

Placebo (n=205)

Valdecoxib 5mg QD
(n=201)

Valdecoxib 10mg QD
(n=205)

Valdecoxib 20mg QD
(n=201)

4.10

4.07

4.09

4.09

-1.31‡ (-1.44, - 1.19)

-1.37‡ (-1.50, -1.25)

-1.42‡ (-1.54, - 1.29)

-1.44* (-1.58, - 1.31)

-1.50† (-1.63, -1.36)

-1.41* (-1.55, - 1.28)

-1.43* (-1.58, -1.28)

-1.52† (-1.67, -1.38)

-1.45* (-1.60, -1.31)

71.41

72.41

72.54

LSM change
Week 2 (CI) -1.04 (-1.16, 0.91)
Week 6 (CI) -1.22 (-1.35, 1.08)
Week 12 (CI) -1.22 (-1.36, 1.08)
PAAP£
Baseline Mean

71.20

LSM change
Week 2 (CI) -21.19 (-24.80, -

-28.46† (-32.11, - 24.82) -30.21‡ (-33.83, -26.59)

-32.07‡(-35.73, -
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17.58)
Week 6 (CI) -23.92 (-27.72, 20.12)
Week 12 (CI) -25.97 (-30.02, 21.92)
WOMAC OA,
Stiffness¶
Baseline Mean 4.84

28.41)
†

*

-30.81 (-34.65, - 26.97) -29.85 (-33.67, -26.04)

-32.28† (-36.13, 28.42)
-32.70* (-36.81, 32.70)

-31.33 (-35.42, - 27.24)

-30.41 (-34.47, -30.41)

4.87

4.91

4.73

-1.03 (-1.24, - 0.82)

-1.20† (-1.41, -0.99)

-1.24† (-1.45, -1.03)

-1.25 (-1.48, - 1.02)

-1.42* (-1.65, -1.20)

-1.43* (-1.66, -1.20)

-1.33 (-1.57, - 1.09)

-1.41 (-1.65, -1.17)

-1.46* (-1.70, -1.22)

53.03

54.73

53.42

LSM change
Week 2 (CI) -0.78 (-0.98, 0.57)
Week 6 (CI) -1.04 (-1.27, 0.82)
Week 12 (CI) -1.12 (-1.36, 0.89)
WOMAC OA,
Composite#
Baseline Mean 53.49
LSM change
Week 2 (CI) -10.13 (-12.28, 7.99)
Week 6 (CI) -12.98 (-15.45, 10.51)
Week 12 (CI) -13.48 (-16.07, 10.89)
*
P < .05 vs placebo, significant.

-13.26* (-15.42, - 11.09) -15.05‡ (-17.20, -12.90)
-15.47 (-17.97, - 12.98)

-16.74* (-19.22, -14.26)

-16.84 (-19.46, - 14.23)

-17.34* (-19.93, -14.74)

†

P < .01 vs placebo, significant.

‡

P < .001 vs placebo, significant.

§

Scale = 1 (very good) to 5 (very poor).

£

Scale = 0 mm (no pain) to 100 mm (most severe pain).

¶

Scale = 0 (no symptoms) to 8 (worse symptoms).

#

Scale = 0 (no symptoms) to 96 (worse symptoms).

-15.44‡ (-17.63, 13.32)
-17.33* (-19.48, 14.51)
-17.22* (-20.64, 15.44)

CI, 95% confidence interval; LSM, least square mean; PAAP, Patient’s Assessment of Arthritis Pain; PhGAA,
Physician’s Global Assessment of Arthritis; QD, once daily; WOMAC OA, Western Ontario and McMaster’s
Universities Osteoarthritis Index.

**This information was pulled directly from Kivitz et al5
Makarowski et al6 had a total of 467 patients randomized in the ITT population, 209
of which withdrew before the end of the study period.6 Withdrawal due to treatment failure
in the Valdecoxib 5mg & 10mg groups was significantly lower than placebo where p≤ 0.05.
It is also noted that withdrawal from the placebo group occurred at a faster rate than any of
the treatment groups.6 This study design was very similar to the one described in Kivitz et al,
so the assessment tools and indices were using the same scales as stated above.
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In assessment of efficacy, it was shown that Valdecoxib 5mg QD & 10mg QD were
significantly superior to placebo for all assessments.6 The only exception to this was in the
PAAP-VAS week 12 assessment where only Valdecoxib 10mg QD was statistically superior
to placebo.6 A summary of the data from Makarowski et al can be found in Tables 3 and 4.
This study included all continuous data that could not be converted to dichotomous data.
Table 3: Makarowski et al6 least square mean changes from baseline for PaGAA,
PhGAA, PAAP-VAS.
Placebo (N=117)

Valdecoxib 5mg QD
(N=120)

Valdecoxib 10mg QD
(N=111)

PaGAA ‡
Baseline mean 4.1
4.1
4.1
LSM change
Week 2 -0.72
-1.10**†
-1.26***†
*†
Week 6 -0.82
-1.11
-1.29***†
*†
Week 12 -0.87
-1.20
-1.29***†
‡
PhGAA
Baseline mean 4.1
4.1
4.1
LSM change
Week 2 -0.72
-1.10**†
-1.22***†
*†
Week 6 -0.84
-1.17
-1.25**†
*
Week 12 -0.88
-1.18
-1.25*
PAAP-VAS§
Baseline mean 71.2
72.3
73.4
LSM change
Week 2 -14.4
-21.0*
-24.6**
*
Week 6 -16.0
-23.3
-25.8**
Week 12 -15.2
-21.3
-23.2*
Statistically significant *P≤0.05 vs placebo, **P≤0.01 vs placebo, ***P<0.001 vs placebo.
†Statistically significantly different from placebo in pairwise comparisons.
‡Scale ranged from 1 (very good) to 5 (very poor).
§Scale ranged from 0–100 mm, with 0=no pain and 100=most severe pain.

*Information was pulled directly from Makarowski et al6
Table 4: Makarowski et al6 least square mean changes from baseline for WOMAC indices.
Placebo (N=117)

Valdecoxib 5mg
QD (N=120)

Valdecoxib 10mg QD
(N=111)

10.8

11.2

10.8

-0.90
-1.09
-1.25

-2.48***‡
-2.76***‡
-2.54*‡

-2.56***‡
-3.23***‡
-2.83**‡

52.6

54.7

52.8

Pain index§
Baseline mean
LSM change
Week 2
Week 6
Week 12
Composite index¶
Baseline mean
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LSM change
Week 2 -4.31
-10.8**
-12.6***
**
Week 6 -5.07
-12.3
-14.7***
**
Week 12 -5.28
-12.0
-14.0***
Statistically significant *P≤0.05 vs placebo, **P≤0.01 vs placebo, ***P<0.001 vs placebo.
‡Statistically significantly different from placebo in pairwise comparisons according to
Hochberg’s procedure.
§Scale ranged from 0 to 20, with lower score as better.
¶Scale ranged from 0 to 96, with lower score as better.

*Information was pulled directly from Makarowski et al6
The study design for Moskowitz et al7 was still looking at efficacy of Valdecoxib, but
not as a long term treatment. They were assessing the quickness of onset of analgesia during
acute pain flare. In order to be included in the ITT population, patients were screened
according to inclusion and exclusion data described in Table 1 and then randomized and
given at least one study medication.7 The ITT population included 435 patients, but 95
patients were then excluded from the per protocol (PP) cohort due to various reasons
described in the study.7
Pain intensity difference (PID) VAS scores were significantly greater in the
Valdecoxib treatment group at 4 hours versus placebo.7 Median time to first onset of
analgesia in the PP cohort was also significantly shorter for Valdecoxib as compared to
placebo. Also, Valdecoxib had significantly improved Summed PID (SPID) scores in the
first 6 hours compared to placebo.7 Analgesic onset in the ITT population showed a
significant percentage of patients with onset of analgesia from 4hrs to 6hrs, shown in Table
5.7 This study included some dichotomous data that could be calculated to show that the
NNT for Valdecoxib 10mg was 7; meaning that 7 patients need to be treated with this
medication in order to have a positive impact on one. This data is shown in Table 6.
Table 5: Percent incidence of onset of analgesia during the first 6hrs in ITT population7
Time (h)
1.0
2.0
3.0

Valdecoxib 10mg QD (n=212)
29
46
50

Placebo (n=110)
28
39
41
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4.0
5.0
6.0
*P < 0.05

55*
56*
58*

40
42
43

*Information pulled directly from Moskowitz et al7
Table 6: Calculated data for treatment using dichotomous data
CER

EER

40%

55%

Relative benefit
increase (RBI)
EER-CER
CER
0.375

Absolute Benefit
increase (ABI)
EER-CER

Number Needed to
treat (NNT)
1/ABI

0.15

7

Where p-value ≤ 0.05 vs placebo

DISCUSSION
The populations studied in each article were relatively similar, with mean age ranging
from 59.7 years to 63.9 years old. All studies had similar inclusion and exclusion criteria,
assuring that all patients were considered to have significant disease before the studies were
done. There were similar results as far as efficacy of Valdecoxib, showing it to be significant
to placebo at doses equal to and greater than 10mg QD. Kivitz et al did not find Valdecoxib
5mg QD to be significant to placebo, requiring further evaluation of a proper daily dosage.5
One aspect of this drug that has been evaluated in other studies is its safety. The
original thought behind COX-2 inhibitors was to improve GI safety compared to NSAIDS,
but drugs like Valdecoxib have displayed safety issues in other areas like cardiovascular
events.8 As part of the sulfonamide class, Valdecoxib already carries increased risk for
reactions including TEN, SJS, and erythema multiforme.8
CONCLUSION
Based on the information provided in these three studies, it has been concluded that
Valdecoxib is an effective treatment for pain in patients with Osteoarthritis of the hip or knee
compared to placebo at doses of 10mg and higher; however, there are several issues with
these studies that would require further examination. One main concern is the withdrawal
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rates for all three articles were very high, reducing the validity of each of them significantly.
Although it was shown by Kivitz et al5 and Makarowski et al6 that withdrawal number and
rates were higher in placebo than treatment groups, there was still a significant amount of
participants withdrawing from experimental groups due to treatment failure.
The second issue with Valdecoxib in general is that in recent studies, safety has been
evaluated leading the FDA to take Valdecoxib off the market completely in 2005.8 Further
studies have clearly showed that the risks outweighed the benefits of Valdecoxib in the
treatment of Osteoarthritis; however there are still many COX-2 inhibitors on the market to
treat Osteoarthritis that did not have the cardiovascular events that Valdecoxib did. By
researching Valdecoxib or other failed treatment options we can provide insight to future
prospects in pain management for Osteoarthritis.
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